This capability is demonstrated by the successful knockdown of strategically selected known modulators of tumor immune evasion validated in vivo such as PD-L1 (24–26), IFNGR2 (27, 28), STAT1 (29–31), MART-1 (32, 33), and MYC (34–36). The gene discussed is IFNGR2; the disease is neoplasm.